Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Belite Bio, Inc
Subjects will be randomized in a 2:1 ratio to receive either tinlarebant or placebo. The study treatment will be administered orally once daily from baseline (Day 1) through the final day of Month 24.
Age
60–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes.
Minimum BCVA is required in the study eye
You may not be if
The presence of diabetic macular edema or macular disease in either eye.
Diabetic retinopathy more advanced than mild nonproliferative diabetic retinopathy, or any other retinal vascular disease in either eye.
Uncontrolled diagnosed glaucoma in the study eye
Clareo Health | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
